GSK
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- GSK reports promising data for its antibody-drug conjugate risvutatug rezetecan (ris-rez) in small cell lung cancerOct 19, 2026
- GSK paid Hutchmed $110 million upfront for rights to a preclinical KRAS- and EGFR-targeted drug with potential applications in colorectal, pancreatic, and lung cancersSep 7, 2026
- Jideytro (zidesamtinib) receives U.S. approval for previously treated ROS1-positive non-small cell lung cancerJul 23, 2026
- Real-world data showed GSK’s AREXVY reduced certain RSV-related risks, including heart attack, stroke, and severe COPD or asthma flare-upsFeb 18, 2026
- Summit Therapeutics announced clinical trial collaboration with GSK for ivonescimab combinationJan 12, 2026